• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Picard Medical, Inc. Announces Closing of $17 Million Initial Public Offering

    9/2/25 4:05:00 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care
    Get the next $PMI alert in real time by email

    TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), today announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the "Common Stock") at $4.00 per share (the "Offering"). The Company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of Common Stock the public offering price, less underwriting discounts, to cover over-allotment, if any. The gross proceeds from the offering were $17 million, before deducting underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American, LLC ("NYSE American") under the ticker symbol "PMI" on August 29, 2025.

    WestPark Capital, Inc. was Lead Manager and Sole Bookrunner for the Offering and representative of the underwriters for the Offering. Sentinel Brokers Co., Inc. was Co-Manager. E.F. Hutton & Co. and Uphorizon, LLC were financial advisors to the issuer.

    The offering was made only by means of a prospectus, copies of which may be obtained from WestPark Capital, Inc. by email at [email protected] or via standard mail to WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA 90067, or from the SEC website at www.sec.gov.

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission ("SEC") on August 12, 2025.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

     About Picard Medical, Inc.

    Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov.

    Contact:

    Investors

    Eric Ribner

    Managing Director

    LifeSci Advisors LLC

    [email protected]

    Picard Medical, Inc./SynCardia Systems, LLC

    [email protected]

    General/Media

    Brittany Lanza

    [email protected]



    Primary Logo

    Get the next $PMI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    J-Star Holding Names Sam Van as Chief Executive Officer

    TAICHUNG CITY, Taiwan, Sept. 22, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (NASDAQ:YMAT) ("J-Star" or the "Company"), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced that Sam Van has been named Chief Executive Officer of J-Star, effective October 1. Mr. Van succeeds Jonathan Chiang, who will continue to serve as Chairman of the Board with a focus on driving continued market innovation and key customers. Mr. Van joins at a pivotal moment for J-Star. Following the Company's recent i

    9/22/25 4:05:00 PM ET
    $PMI
    $REED
    $YMAT
    Medical/Dental Instruments
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Picard Advances Patent Protection for Fully Implantable Artificial Heart Technology

    - Patent portfolio secures innovation for the future of heart replacement - TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No. 12,383,722 B2 covering systems and methods related to its next-generation SynCardia Total Artificial Heart (STAH), the "Emperor." This recently granted patent, relating to the apparatus, systems, and methods for enabling a next-generation total artificial heart w

    9/22/25 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Reports Second Quarter 2025 Financial Results

    Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early September, Picard successfully closed its initial public offering, raising gross proceeds of $19.5 million. "Our second quarter results reflect strong sales growth for the SynCardia total artif

    9/15/25 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    SEC Filings

    View All

    SEC Form DEF 14A filed by Picard Medical Inc.

    DEF 14A - Picard Medical, Inc. (0002030617) (Filer)

    9/29/25 5:12:16 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Picard Medical Inc.

    PRE 14A - Picard Medical, Inc. (0002030617) (Filer)

    9/18/25 4:05:43 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    9/10/25 4:15:35 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care